Concomitant hypertension in patients with hypertrophic cardiomyopathy was associated with an increased risk of all-cause mortality (HR 1.32; 95% CI 1.04-1.69; p=0.024).
Cohort (n=2,873)
Yes
Does concomitant hypertension increase all-cause mortality in patients with hypertrophic cardiomyopathy?
In patients with hypertrophic cardiomyopathy, concomitant hypertension is associated with a distinct CMR phenotype and an increased risk of long-term all-cause mortality.
Hazard Ratio: 1.32 (95% CI 1.04–1.69)
p-value: p=0.024
AIMS: To characterize the cardiovascular magnetic resonance (CMR) phenotype of hypertensive hypertrophic cardiomyopathy (HCM) patients, assess the association between hypertension and all-cause mortality, and compare the long-term prognostic performance of CMR-derived biomarkers between hypertensive versus non-hypertensive HCM patients. METHODS: Between 2008 and 2024, all consecutive HCM patients referred for CMR from the HCM-LGE registry were included. The primary outcome was all-cause mortality. Clinical variables, cardiac volumes, myocardial mass, functions and tissue characterization with late gadolinium enhancement (LGE) were assessed in all patients. The prognostic value of hypertension and CMR-derived biomarkers were assessed using survival analysis. RESULTS: Among 2,873 patients with HCM (52±8 years, 56% males), 796 (28%) had hypertension. Hypertensive HCM patients had greater LGE extent (1.1±1.8 vs 0.9±1.5, p3 segments and septal location of LGE were independently associated with mortality in hypertensive HCM patients (HR: 3.99 95%CI: 2.21-7.18; p=<0.001 and HR: 1.76 95%CI: 1.03-3.01; p=0.039, respectively) and non-hypertensive HCM patients (HR: 4.63 95%CI: 2.15-9.97; p<0.001 and HR: 1.48 95%CI: 1.02-2.15; p=0.040, respectively). CONCLUSION: In a large multicenter cohort of HCM patients, concomitant hypertension was associated with increased long-term mortality and prognostic associations of CMR-LGE biomarkers were found. These findings highlight the importance of comprehensive cardiovascular risk assessment in HCM patients.
Florence et al. (Mon,) conducted a cohort in Hypertrophic cardiomyopathy (n=2,873). Hypertension vs. Non-hypertensive was evaluated on All-cause mortality (HR 1.32, 95% CI 1.04-1.69, p=0.024). Concomitant hypertension in patients with hypertrophic cardiomyopathy was associated with an increased risk of all-cause mortality (HR 1.32; 95% CI 1.04-1.69; p=0.024).